Determining the impact of an artificial intelligence tool on the management of pulmonary nodules detected incidentally on CT (DOLCE) study protocol: a prospective, non-interventional multicentre UK study

Author:

O'Dowd EmmaORCID,Berovic Marko,Callister Matthew,Chalitsios Christos V,Chopra Disha,Das Indrajeet,Draper Adrian,Garner Justin L,Gleeson Fergus,Janes Sam,Kennedy Martyn,Lee Richard,Mauri Fabrizio,McKeever Tricia MORCID,McNulty William,Murray James,Nair Arjun,Park John,Rawlinson Janette,Sagoo Gurdeep SinghORCID,Scarsbrook Andrew,Shah Pallav,Sudhir Rajini,Talwar Ambika,Thakrar Ricky,Watkins Johnathan,Baldwin David R

Abstract

IntroductionIn a small percentage of patients, pulmonary nodules found on CT scans are early lung cancers. Lung cancer detected at an early stage has a much better prognosis. The British Thoracic Society guideline on managing pulmonary nodules recommends using multivariable malignancy risk prediction models to assist in management. While these guidelines seem to be effective in clinical practice, recent data suggest that artificial intelligence (AI)-based malignant-nodule prediction solutions might outperform existing models.Methods and analysisThis study is a prospective, observational multicentre study to assess the clinical utility of an AI-assisted CT-based lung cancer prediction tool (LCP) for managing incidental solid and part solid pulmonary nodule patients vs standard care. Two thousand patients will be recruited from 12 different UK hospitals. The primary outcome is the difference between standard care and LCP-guided care in terms of the rate of benign nodules and patients with cancer discharged straight after the assessment of the baseline CT scan. Secondary outcomes investigate adherence to clinical guidelines, other measures of changes to clinical management, patient outcomes and cost-effectiveness.Ethics and disseminationThis study has been reviewed and given a favourable opinion by the South Central—Oxford C Research Ethics Committee in UK (REC reference number: 22/SC/0142).Study results will be available publicly following peer-reviewed publication in open-access journals. A patient and public involvement group workshop is planned before the study results are available to discuss best methods to disseminate the results. Study results will also be fed back to participating organisations to inform training and procurement activities.Trial registration numberNCT05389774.

Funder

UK Research and Innovation

NHS Accelerated Access Collaborative

Publisher

BMJ

Reference10 articles.

1. Cancer Research UK . Cancer mortality for common cancers. 2022. Available: https://www.cancerresearchuk.org/health-professional/cancer-statistics/mortality/common-cancers-compared

2. Lung-cancer screening and the NELSON trial;Lindholt;N Engl J Med,2020

3. Reduced Lung-Cancer Mortality with Volume CT Screening in a Randomized Trial

4. Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening

5. The British Thoracic Society guidelines on the investigation and management of pulmonary nodules

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3